Monday, May 20, 2024

Tag: Vaxzevria

The European Medicines Agency’s (EMA) safety committee has added another blood condition to the potential side effects of AstraZeneca’s vaccine branded as Covishield in India - the Capillary Leak Syndrome.
AstraZeneca has rebranded and changed the name of its COVID-19 vaccine from CoviShield to Vaxzevria. The move is because the company is struggling to convince people that the vaccine is safe amidst the controversy that AstraZeneca COVID-19 vaccine is causing blood clots.